P. Dennis

P. Dennis, R. Flaumenhaft, F. Blei, 1990, Cell differentiation and development : the official journal of the International Society of Developmental Biologists.

Importance of the Stress Kinase p38α in Mediating the Direct Cytotoxic Effects of the Thalidomide Analogue, CPS49, in Cancer Cells and Endothelial Cells

P. Dennis, W. Figg, N. Warfel, 2006, Clinical Cancer Research.

Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells

J. LoPiccolo, J. Gills, P. Dennis, 2012, Cell Death and Disease.

Disparities in Cancer Funding

P. Dennis, 2004, Science.

Modulating protein kinase C (PKC) to increase the efficacy of chemotherapy: stepping into darkness.

P. Dennis, P. Lorenzo, 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors

J. Gills, P. Dennis, C. Hann, 2015, Anticancer Research.

Rapamycin prevents the development and progression of mutant EGFR lung tumors with the acquired resistance mutation T790M

P. Jänne, W. Pao, P. Dennis, 2014 .

PTEN hamartomatous tumor syndromes

P. Dennis, J. Rich, S. Sathornsumetee, 2006 .

PPARγ agonists follow an unknown TRAIL in lung cancer

P. Dennis, S. Lipkowitz, 2007 .

Metabolism of [3H]leupeptin by rat liver.

P. Dennis, N. Aronson, 1985, Archives of biochemistry and biophysics.

Uptake and degradation of 125I-labeled rat asialoorosomucoid by the perfused rat liver.

P. Dennis, N. Aronson, 1984, Biochimica et biophysica acta.

Targeting Akt in cancer therapy.

J. LoPiccolo, J. Gills, P. Dennis, 2007, Anti-cancer drugs.

Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.

S. Sridhar, N. Rizvi, N. Segal, 2019, Clinical lung cancer.

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial.

D. Planchard, C. Faivre-Finn, S. Senan, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Perifosine: Update on a novel Akt inhibitor

J. Gills, P. Dennis, Joell J. Gills, 2009, Current oncology reports.

Antibiotics and Immunotherapy: Too Much of Anything is Bad!

V. Gopalakrishnan, P. Dennis, B. Sellman, 2020, European urology.

Three-year overall survival update from the PACIFIC trial.

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Journal of Clinical Oncology.

Ceramide mediates nanovesicle shedding and cell death in response to phosphatidylinositol ether lipid analogs and perifosine

J. LoPiccolo, J. Gills, P. Dennis, 2012, Cell Death and Disease.

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.

Keunchil Park, N. Rizvi, J. Mazières, 2020, Lung cancer.

A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN

S. Hewitt, R. Memmott, P. Dennis, 2019, The oncologist.

Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer

R. Memmott, J. Gills, P. Dennis, 2014, Oncotarget.

Chemotherapeutic Resistance Promotes Cellular Survival and δ Lung Cancer Cells : PKC Altered Protein Kinase C ( PKC ) Isoforms in Non-Small Cell

P. Dennis, K. West, A. Clark, 2003 .

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

G. Mills, N. Rosen, P. Dennis, 2003, Oncogene.

The effects of low temperature and chloroquine on 125I-insulin degradation by the perfused rat liver.

P. Dennis, N. Aronson, 1981, Archives of biochemistry and biophysics.

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2018, The New England journal of medicine.

Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer.

D. Planchard, C. Faivre-Finn, S. Senan, 2021, Future oncology.

GTP gamma S loading of endothelial cells stimulates phospholipase C and uncouples ATP receptors.

P. Dennis, K. Griendling, P. Davies, 1988, The American journal of physiology.

LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin.

R. Memmott, P. Dennis, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT

C. Faivre-Finn, J. Vansteenkiste, P. Dennis, 2018, Journal of Thoracic Oncology.

Alpha 2-macroglobulin is a binding protein for basic fibroblast growth factor.

D. Rifkin, P. Dennis, O. Saksela, 1989, The Journal of biological chemistry.

Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy

J. LoPiccolo, J. Gills, P. Dennis, 2008, Autophagy.

Induction of preneoplastic lung lesions in guinea pigs by cigarette smoke inhalation and their exacerbation by high dietary levels of vitamins C and E.

E. Fiala, P. Dennis, D. Desai, 2005, Carcinogenesis.

Human smooth muscle α-actin gene is a transcriptional target of the p53 tumor suppressor protein

K. A. Comer, P. Dennis, M. Kastan, 1998, Oncogene.

Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

J. Taube, Q. K. Li, H. Kitagawa, 2016, Cancer research.

The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt

J. Gills, P. Dennis, Joell J. Gills, 2004, Expert opinion on investigational drugs.

Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes.

F. Kaye, E. Rozenblum, I. Kirsch, 2005, Cancer research.

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

J. LoPiccolo, P. Dennis, G. Blumenthal, 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway

R. Memmott, J. Gills, P. Dennis, 2006, Clinical Cancer Research.

Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor.

D. Rifkin, P. Dennis, P. A. Dennis, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Regulation of RhoB Gene Expression during Tumorigenesis and Aging Process and Its Potential Applications in These Processes

P. Dennis, N. Zhang, H. Tian, 2019, Cancers.

Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis

R. Memmott, P. Dennis, S. Kawabata, 2010, Cancer Prevention Research.

Loss of Cytoplasmic CDK1 Predicts Poor Survival in Human Lung Cancer and Confers Chemotherapeutic Resistance

C. Harris, W. Travis, J. Jen, 2011, PloS one.

Molecular pathways and therapeutic targets in lung cancer

Ravi Salgia, Raphael Bueno, R. Bueno, 2014, Oncotarget.

Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.

P. Dennis, M. Nau, S. Lipkowitz, 2001, Cancer research.

Control of PD-L 1 Expression by Oncogenic Activation of the AKT – mTOR Pathway in Non – Small Cell Lung Cancer

J. Taube, Q. K. Li, H. Kitagawa, 2016 .

Activation of the PI3K/Akt pathway and chemotherapeutic resistance.

P. Dennis, K. West, Phillip A Dennis, 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.

J. Gills, P. Dennis, K. West, 2005, Cancer research.

Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling

Brendan J. Quinn, H. Kitagawa, R. Memmott, 2013, Cancer Prevention Research.

A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.

L. Seymour, M. Tsao, D. Tu, 2020, Lung cancer.

Akt-dependent and -independent mechanisms of mTOR regulation in cancer.

R. Memmott, P. Dennis, Phillip A Dennis, 2009, Cellular signalling.

Combining Nelfinavir With Chloroquine Inhibits In Vivo Growth of Human Lung Cancer Xenograft Tumors

J. LoPiccolo, J. Gills, P. Dennis, 2021, In Vivo.

Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.

G. Giaccone, M. Raffeld, E. Szabo, 2013, Clinical Lung Cancer.

The Role of the Akt/mTOR Pathway in Tobacco Carcinogen–Induced Lung Tumorigenesis

R. Memmott, P. Dennis, 2009, Clinical Cancer Research.

Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells.

C. Harris, S. Swain, S. Belinsky, 2003, The Journal of clinical investigation.

Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer.

W. Linehan, C. Ricketts, C. Vocke, 2013, The Journal of urology.

Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/- mice.

P. Dennis, M. C. Hollander, M. Anver, 2008, Neoplasia.

Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.

B. Kemp, R. Memmott, J. Gills, 2008, Cancer research.

Small Cell Lung Cancer Cells − LKB 1-Mutant Non Dependent Death in − AMP-Activated Protein Kinase Phosphatidylinositol Ether Lipid Analogues Induce

B. Kemp, R. Memmott, J. Gills, 2008 .

PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study

N. Rizvi, J. Mazières, J. Vansteenkiste, 2017 .

Repositioning HIV protease inhibitors as cancer therapeutics

P. Dennis, Wendy B Bernstein, Phillip A Dennis, 2008, Current opinion in HIV and AIDS.

Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.

N. Rizvi, P. Dennis, M. Garassino, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An overview of lung cancer genomics and proteomics.

P. Dennis, Courtney A. Granville, 2005, American journal of respiratory cell and molecular biology.

Coronary artery calcium can predict all-cause mortality and cardiovascular events on low-dose CT screening for lung cancer

P. Dennis, Takefumi Komiya, Phillip A. Dennis, 2012 .

A pilot study of sirolimus (S) in subjects with Cowden syndrome (CS) with germ-line mutations in PTEN.

S. Hewitt, R. Memmott, P. Dennis, 2013 .

The Chemopreventive Agent Myoinositol Inhibits Akt and Extracellular Signal-Regulated Kinase in Bronchial Lesions from Heavy Smokers

S. Lam, R. Memmott, J. Gills, 2009, Cancer Prevention Research.

Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade.

Song Wu, J. Barrett, M. Hellmann, 2020, Cancer discovery.

PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development.

J. LoPiccolo, P. Dennis, M. Ballas, 2007, Critical reviews in oncology/hematology.

Management of Reproductive Health in Cowden Syndrome Complicated by Endometrial Polyps and Breast Cancer

P. Dennis, G. Blumenthal, P. Stratton, 2013, Obstetrics and gynecology.

Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo

Robert H. Shoemaker, William D. Figg, Erin R. Gardner, 2007, Clinical Cancer Research.

Tumor kinetic modeling and identification of predictive factors for tumor response to durvalumab in patients with non-small cell lung cancer (NSCLC).

B. Wang, A. Gupta, P. Dennis, 2017 .

Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors.

W. Travis, J. Jen, S. Hewitt, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PTEN hamartoma tumor syndromes

P. Dennis, G. Blumenthal, 2008, European Journal of Human Genetics.

Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in non-small-cell lung cancer patients and is reversed by STAT3 knockdown.

Ricardo J. Miragaia, Y. Shrestha, Song Wu, 2021, Cancer discovery.

Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

Ricardo J. Miragaia, Y. Shrestha, J. Barrett, 2021 .

SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.

C. Rudin, J. Gills, P. Dennis, 2014, Lung cancer.

Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma.

S. Steinberg, J. LoPiccolo, P. Dennis, 2007, Lung cancer.

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).

C. Faivre-Finn, S. Senan, L. Paz-Ares, 2020, Lung cancer.

Nelfinavir Inhibits Maturation and Export of Herpes Simplex Virus 1

P. Dennis, P. Desai, W. Gibson, 2014, Journal of Virology.

Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt.

P. Dennis, J. Brognard, A. Kozikowski, 2003, Journal of the American Chemical Society.

A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors

S. Steinberg, C. Helsabeck, J. LoPiccolo, 2014, Oncotarget.

A Central Role for Foxp3+ Regulatory T Cells in K-Ras-Driven Lung Tumorigenesis

S. Steinberg, J. LoPiccolo, R. Memmott, 2009, PloS one.

Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status

A. Gupta, P. Vicini, P. Dennis, 2018, Clinical pharmacology and therapeutics.

Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.

P. Jänne, W. Pao, Kwok-Kin Wong, 2014, Cell reports.

Targeting Aberrant Signal Transduction Pathways in Lung Cancer

J. Gills, P. Dennis, Courtney A. Granville, 2004, Cancer biology & therapy.

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.

P. Dennis, B. Cho, Yiduo Zhang, 2019, The Lancet. Oncology.

Nelfinavir , ALeadHIVProtease Inhibitor , Is aBroad-Spectrum , AnticancerAgent that InducesEndoplasmicReticulum Stress , Autophagy , andApoptosis Invitro and Invivo

R. Shoemaker, P. Steeg, Carolyn J. M. Best, 2007 .

Studies on the role of basic fibroblast growth factor in vivo: Inability of neutralizing antibodies to block tumor growth

D. Rifkin, P. Dennis, 1990, Journal of cellular physiology.

Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone

P. Jänne, A. Vortmeyer, W. Pao, 2015, OncoTarget.

Phosphatidylinositol Ether Lipid Analogues That Inhibit AKT Also Independently Activate the Stress Kinase, p38α, through MKK3/6-independent and -dependent Mechanisms*

Jiahuai Han, R. Memmott, J. Gills, 2007, Journal of Biological Chemistry.

Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues.

P. Dennis, J. Brognard, K. West, 2004, Cancer research.

Ether Lipid Analogues Cancer Cells by Rationally Designed Phosphatidylinositol Preferential Inhibition of Akt and Killing of Akt-Dependent

P. Dennis, J. Brognard, K. West, 2004 .

Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium.

A. Patenaude, L. Strong, M. Greene, 2012, Cancer genetics.

Nicotine Does Not Enhance Tumorigenesis in Mutant K-Ras–Driven Mouse Models of Lung Cancer

P. Dennis, M. C. Hollander, R. Linnoila, 2011, Cancer Prevention Research.

Identification of a Highly Effective Rapamycin Schedule that Markedly Reduces the Size, Multiplicity, and Phenotypic Progression of Tobacco Carcinogen–Induced Murine Lung Tumors

T. Veenstra, H. Issaq, P. Dennis, 2006, Clinical Cancer Research.

A Cyp2a polymorphism predicts susceptibility to NNK-induced lung tumorigenesis in mice.

P. Dennis, M. C. Hollander, A. Patterson, 2011, Carcinogenesis.

Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab

A. Gupta, P. Dennis, R. Raja, 2018, Clinical Cancer Research.

93TiP MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy

M. Tsuboi, C. Swanton, M. Ahn, 2021 .

P03.03 MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery

M. Tsuboi, C. Swanton, M. Ahn, 2021 .

LBA1_PRPACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC

D. Planchard, L. Paz-Ares, P. Dennis, 2017 .

Tumor shrinkage and increased overall survival are associated with improved albumin, neutrophil lymphocyte ratio (NLR) and decreased durvalumab clearance in NSCLC and UC patients receiving durvalumab.

T. Powles, A. Gupta, P. Dennis, 2017 .

Using immmunotherapy to target EGF in patients with NSCLC

P. Dennis, D. O'mahony, 2006, Cancer biology & therapy.

Comment on: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. Author's reply

F. Cappuzzo, P. Dennis, J. Tsurutani, 2004 .

Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)

C. Faivre-Finn, J. Vansteenkiste, P. Dennis, 2019, Annals of Oncology.

A phase II, open-label, multi-arm study of novel combinations of immunotherapies or DDR inhibitors in platinum-refractory, extensive disease small-cell lung cancer (ED-SCLC): BALTIC.

Haiyi Jiang, P. Dennis, I. Vynnychenko, 2017 .

Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt

S. Hewitt, S. Holbeck, J. Gills, 2006, Molecular Cancer Therapeutics.

Germline PTEN mutations as a cause of early-onset endometrial cancer.

P. Dennis, G. Blumenthal, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PL 02.02 Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC

P. Dennis, B. Cho, S. Antonia, 2017 .

Expression Signatures of the Lipid-Based Akt Inhibitors Phosphatidylinositol Ether Lipid Analogues in NSCLC Cells

R. Greil, R. Weichselbaum, G. Prendergast, 2011, Molecular Cancer Therapeutics.

Three-year overall survival update from the PACIFIC trial

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Annals of Oncology.

Tobacco carcinogen-induced cellular transformation increases Akt activation in vitro and in vivo.

C. Harris, S. Belinsky, P. Dennis, 2004, Chest.

A phase I study of nelfinavir, an FDA approved HIV protease inhibitor, in adults with refractory solid tumors.

C. Helsabeck, J. LoPiccolo, P. Dennis, 2009, Journal of Clinical Oncology.

Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

P. Dennis, J. Brognard, A. Clark, 2001, Cancer research.

Somatic STK11/LKB1 mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC.

Song Wu, A. Gupta, P. Dennis, 2018 .

82ODurvalumab in ≥ 3rd-line EGFR mutant/ALK+, locally advanced or metastatic NSCLC: Results from the phase 2 ATLANTIC study

N. Rizvi, J. Mazières, P. Dennis, 2017 .

Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC)

C. Faivre-Finn, S. Senan, D. Raben, 2019, International Journal of Radiation Oncology*Biology*Physics.

Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC.

C. Faivre-Finn, S. Senan, D. Raben, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 3, randomized study of first-line durvalumab (D) ± tremelimumab (T) + platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): Caspian.

Haiyi Jiang, L. Paz-Ares, P. Dennis, 2017 .

Akt-dependent and -independent mechanisms of mTOR regulation in cancer.

R. Memmott, P. Dennis, 2009, Cellular signalling.

The Role of the Akt/mTOR Pathway in Tobacco Carcinogen–Induced Lung Tumorigenesis

R. Memmott, P. Dennis, 2009, Clinical Cancer Research.

Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.

P. Dennis, J. Tsurutani, 2004, Journal of the National Cancer Institute.

P2.04-002 CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC

Haiyi Jiang, P. Dennis, Y. Huang, 2017 .

Abstract 4981: PI3K/AKT/mTOR pathway activation drives expression of the immune inhibitory ligand PD-L1 in NSCLC.

P. Dennis, W. Wilson, Kristin J. Lastwika, 2013 .

Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors

P. Dennis, C. Hann, S. Kawabata, 2021, Anticancer Research.

PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC

P. Dennis, Y. Wu, Y. Cheng, 2019, Annals of Oncology.